Entries from India Chemicals Blog tagged with 'pharmaceuticals'
More changes at Jubilant?
Jubilant Organosys appears to be taking one more step in transforming itself into a pharmaceutical company. The company is looking at selling its industrial and performance products division and expects to realise Rs3.0-3.5bn from the sale, says this report in...
Not so fine anymore?
News is slowly trickling in of Indian pharmaceutical and fine chemical companies shutting down facilities that were acquired with great zeal during the 2005-08 overseas acquisition drive. Shasun has decided to shut its facility at Newbie in Scotland and is...
Sign of things to come?
The big news today is Daiichi Sankyo's acquisition of a controlling stake in Ranbaxy, India's largest pharmaceutical company, for $4.6bn. Analysts have been quick to predict many more such deals which will see international pharma majors entering the generic space....
Struggling with Reach
Are Indian chemical companies ready for Reach? Apparently not, says this report in today's Mint. The problem appears to be not only lack of awareness about the EU programme for registration, evaluation and authorisation of chemicals (Reach) but also a...
Pharma still keen on M&As
The Indian pharmaceutical sector is keeping the M&A fire burning with six deals concluded last month, up from eight in the January-March period. The list includes Jubilant Organosys' $255m acquisition of US-based DRAXIS Health and the $218m buyout of Dabur...
Matrix mulls Docpharma sale
Have Indian fine chemical and pharma companies been too hasty in their global acquisitions? I had been hearing talk of some companies running into integration problems or having second thoughts on perceived benefits of their acquisitions. But today’s report that...
Testing times for CRAMS
Business is booming in India’s custom research and manufacturing services (CRAMS) industry thanks to the country's strong process chemistry skills, low operational costs and the availability of a skilled workforce. Frost & Sullivan values the Indian CRAMS market at $890m,...
Cashing in on APIs
How big is the opportunity for Indian active pharmaceutical ingredients' (API) manufacturers? Here is an estimate presented by Satish Khanna, group president, API, Lupin Ltd, at the Speciality Chemicals Conclave in Mumbai last week. To develop his estimate, Khanna first...
CRAMs comes with challenges
India’s success in the global custom research and manufacturing services space (CRAMS) is well documented. And the untapped potential is huge especially as western pharmaceutical companies remain under pressure to cut costs. According to one estimate, the global manufacturing outsourcing...
CRAMS: still going strong
Indian companies in the contract research and manufacturing services (CRAMS) domain appear to be doing well as is reflected in the stock market performance of these companies. The list includes Divi’s Laboratories, Dishman Pharmaceuticals & Chemicals, Nicholas Piramal, Shasun Chemicals...
Engineers are hot
There is fresh competition for Indian engineers. After IT, it is the turn of the legal outsourcing sector with engineers being recruited to work in the area of patents and intellectually property rights, says this report. Engineers are being hired...
Opportunties in CRAMS
With an estimated annual growth of 25%, the Indian contract research and manufacturing services (CRAMS) sector is attracting global attention. Globally, drugs worth $70 billion would be going off-patent by 2011 and Indian companies providing contract manufacturing services are expected...
Feed Subscription
If you use an RSS reader, you can subscribe to a feed of all future entries tagged 'pharmaceuticals'. [What is this?]
